Bevacizumab-induced alterations in vascular permeability and drug delivery: A novel approach to augment regional chemotherapy for in-transit melanoma

Clinical Cancer Research

Volumn 18, Issue 12, 2012, Pages 3328-3339

  Turley, Ryan S ^a,b   Fontanella, Andrew N ^a   Padussis, James C ^a,b   Toshimitsu, Hiroaki ^a,b   Tokuhisa, Yoshihiro ^a,b   Cho, Eugenia H ^a   Hanna, Gabi ^a   Beasley, Georgia M ^a   Augustine, Christina K ^a   Dewhirst, Mark W ^a   Tyler, Douglas S ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EVANS BLUE; HEMOGLOBIN; MELPHALAN; OXYGEN; SODIUM CHLORIDE; VASCULOTROPIN;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD GAS PARAMETERS; BLOOD VESSEL PERMEABILITY; CANCER SIZE; CANCER TISSUE; CONTROLLED STUDY; DIFFUSE REFLECTANCE SPECTROSCOPY; DNA ADDUCT; DRUG EFFICACY; DRUG INFUSION; DRUG PENETRATION; DRUG POTENTIATION; DRUG UPTAKE; FEMALE; FEMUR; HEMOGLOBIN OXYGEN SATURATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN-TRANSIT MELANOMA; INTRAVITAL MICROSCOPY; ISOLATED LIMB INFUSION; LIMB DISEASE; MELANOMA; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; REGIONAL PERFUSION; SINGLE DRUG DOSE; SPECTROPHOTOMETRY; TISSUE PRESSURE; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MELANOMA; MELPHALAN; MICE; MICE, INBRED BALB C; MICE, NUDE; OXYGEN CONSUMPTION; RATS; RATS, NUDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862561507     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3000     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. de Vries E, Bray FI, Coebergh JW, Parkin DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003;107: 119-26. (Pubitemid 37100095)
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
4. Pawlik TM, Ross MI, Johnson MM, Schacherer CW, McClain DM, Mansfield PF, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2005;12:587-96. (Pubitemid 41126088)
5. Turley RS, Raymond AK, Tyler DS. Regional treatment strategies for intransit melanoma metastasis. Surg Oncol Clin N Am 2011;20:79-103.
6. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 2009;23:488-96.
7. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998;14:238-47. (Pubitemid 28146516)
8. Sharma K, Beasley GM, Turley RS, Broadwater G, Petersen B, Mosca P, et al. Patterns of recurrence following complete response to regional chemotherapy for in-transit melanoma. Ann Surg Oncol. 2012 Apr 3. [Epub ahead of print].
9. Rofstad EK, Mathiesen B. Metastasis in melanoma xenografts is associated with tumor microvascular density rather than extent of hypoxia. Neoplasia 2010;12:889-98.
10. Mahabeleshwar GH, Byzova TV. Angiogenesis in melanoma. Semin Oncol 2007;34:555-65. (Pubitemid 350236307)
11. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62. (Pubitemid 40093472)
12. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80. (Pubitemid 35266299)
13. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-71.
14. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
15. Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009;27:2645-52.
16. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40.
17. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N Engl J Med 2004;350:2335-42. (Pubitemid 38702844)
18. Pallis AG, Serfass L, Dziadziusko R, van Meerbeeck JP, Fennell D, Lacombe D, et al. Targeted therapies in the treatment of advanced/ metastatic NSCLC. Eur J Cancer 2009;45:2473-87.
19. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007;13: 3942-50. (Pubitemid 47037602)
20. Palmer GM,Fontanella AN, Shan S, Hanna G, Zhang G, Fraser CL, et al. In vivo optical molecular imaging and analysis in mice using dorsal window chamber models applied to hypoxia, vasculature and fluorescent reporters. Nat Protoc 2011;6:1355-66.
21. Skala MC, Fontanella A, Lan L, Izatt JA, Dewhirst MW. Longitudinal optical imaging of tumor metabolism and hemodynamics. J Biomed Opt 2010;15:011112.
22. Dewhirst MW, Chitneni SK, Palmer GM, Zalutsky MR. Molecular imaging of hypoxia. J Nucl Med 2011;52:165-8.
23. Augustine CK, Yoshimoto Y, Gupta M, Zipfel PA, Selim MA, Febbo P, et al. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res 2008;68:3777-84.
24. Attis MG, Burchette JL, Selim MA, Pham T, Soler AP. Differential expression of N-cadherin distinguishes a subset of metastasizing desmoplastic melanomas. Hum Pathol 2006;37:899-905. (Pubitemid 43902952)
25. Tilby MJ, Styles JM, Dean CJ. Immunological detection of DNA damage caused by melphalan using monoclonal antibodies. Cancer Res 1987;47:1542-6. (Pubitemid 17044480)
26. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007;13:3395-402. (Pubitemid 46944928)
27. Erhard H, Rietveld FJ, van Altena MC, Brocker EB, Ruiter DJ, de Waal RM. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res 1997;7 Suppl 2:S19-26. (Pubitemid 27501622)
28. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996;93:14765-70. (Pubitemid 26419043)
29. Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986;46:5629-32. (Pubitemid 17177959)
30. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-6. (Pubitemid 38697278)
31. Palmer GM, Viola RJ, Schroeder T, Yarmolenko PS, Dewhirst MW, Ramanujam N. Quantitative diffuse reflectance and fluorescence spectroscopy: tool to monitor tumor physiology in vivo. J Biomed Opt 2009;14:024010.
32. Papenfuss HD, Gross JF, Intaglietta M, Treese FA. A transparent access chamber for the rat dorsal skin fold. Microvasc Res 1979;18:311-8. (Pubitemid 10180862)
33. Cao Y, Sonveaux P, Liu S, Zhao Y, Mi J, Clary BM, et al. Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Res 2007;67:3835-44. (Pubitemid 46762171)
34. Augustine CK, Toshimitsu H, Jung SH, Zipfel PA, Yoo JS, Yoshimoto Y, et al. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol Cancer Ther 2010;9:2090-101.
35. Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in preclinical models. Microcirculation 2010;17:206-25.
36. Jain RK, Duda DG, Clark JW, Loef fler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40. (Pubitemid 43108832)
37. Teicher BA. A systems approach to cancer therapy. (Antioncogenics+ standard cytotoxics->mechanism(s) of interaction). Cancer Metastasis Rev 1996;15:247-72.
38. Eichhorn ME, Strieth S, Luedemann S, Kleespies A, Noth U, Passon A, et al. Contrast enhanced MRI and intravital fluorescence microscopy indicate improved tumor microcirculation in highly vascularized melanomas upon short-term anti-VEGFR treatment. Cancer Biol Ther 2008;7:1006-13.
39. Ohta M, Kawabata T, Yamamoto M, Tanaka T, Kikuchi H, Hiramatsu Y, et al. TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model. Surg Today 2009;39:1046-53.
40. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010;70:6171-80.
41. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95. (Pubitemid 46075199)
42. Netti PA, Hamberg LM, Babich JW, Kierstead D, Graham W, Hunter GJ, et al. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci U S A 1999;96: 3137-42. (Pubitemid 29148857)
43. Greig NH, Sweeney DJ, Rapoport SI. Melphalan concentration dependent plasma protein binding in healthy humans and rats. Eur J Clin Pharmacol 1987;32:179-85. (Pubitemid 17053294)
44. Hainsworth JD, Infante JR, Spigel DR, Peyton JD, Thompson DS, Lane CM, et al. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 2010;116:4122-9.
45. Vihinen PP, Hernberg M, Vuoristo MS, Tyynela K, Laukka M, Lundin J, et al. A phase II trial of bevacizumab with dacarbazine and daily lowdose interferon-alpha2a as first line treatment in metastatic melanoma. Melanoma Res 2010;20:318-25.
46. PerezDG,SumanVJ, Fitch TR,AmatrudaT III,MortonRF, Jilani SZ,et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 2009;115:119-27.
47. O'Day SJ, Kim KB, Sosman JA, Peterson AC, Feng S, Minor DR, et al. BEAM: a randomized phase II study evaluating the activity of Bevacizumab in combination with carboplatin plus placitaxel in patients with previously untreated advanced melanoma. Eur J Cancer 2009;7:13.
48. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011;29:11-6.
49. Beasley GM, Riboh JC, Augustine CK, Zager JS, Hochwald SN, Grobmyer SR, et al. Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol 2011;29: 1210-5.
50. McMahon NGB, Sanders G, Augustine C, Tyler DS. A phase I study of systemic sorafenib in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma. J Clin Oncol 2009;27:Abstr 9065.